Ototoxicity evaluation in medulloblastoma patients treated with involved field boost using intensity-modulated radiation therapy (IMRT): a retrospective review by Vieira, Wilson Albieri et al.
  Universidade de São Paulo
 
2014
 
Ototoxicity evaluation in medulloblastoma
patients treated with involved field boost using
intensity-modulated radiation therapy (IMRT):
a retrospective review
 
 
Radiation Oncology. 2014 Jul 21;9(1):158
http://dx.doi.org/10.1186/1748-717X-9-158
 
Downloaded from: Biblioteca Digital da Produção Intelectual - BDPI, Universidade de São Paulo
Biblioteca Digital da Produção Intelectual - BDPI
Departamento de Pediatria - FM/MPE Artigos e Materiais de Revistas Científicas - FM/MDR
RESEARCH Open Access
Ototoxicity evaluation in medulloblastoma
patients treated with involved field boost using
intensity-modulated radiation therapy (IMRT):
a retrospective review
Wilson Albieri Vieira1,2*, Eduardo Weltman1,2, Michael Jenwei Chen1, Nasjla Saba da Silva3,
Andrea Maria Cappellano3, Liliane Desgualdo Pereira4, Maria Ines Rabelo Gonçalves4, Robson Ferrigno1,
Rodrigo Morais Hanriot1, Wladimir Nadalin1,2, Vicente Odone Filho5 and Antonio Sergio Petrilli3
Abstract
Background: Ototoxicity is a known side effect of combined radiation therapy and cisplatin chemotherapy for the
treatment of medulloblastoma. The delivery of an involved field boost by intensity modulated radiation therapy
(IMRT) may reduce the dose to the inner ear when compared with conventional radiotherapy. The dose of cisplatin
may also affect the risk of ototoxicity. A retrospective study was performed to evaluate the impact of involved field
boost using IMRT and cisplatin dose on the rate of ototoxicity.
Methods: Data from 41 medulloblastoma patients treated with IMRT were collected. Overall and disease-free
survival rates were calculated by Kaplan-Meier method Hearing function was graded according to toxicity criteria of
Pediatric Oncology Group (POG). Doses to inner ear and total cisplatin dose were correlated with hearing function
by univariate and multivariate data analysis.
Results: After a mean follow-up of 44 months (range: 14 to 72 months), 37 patients remained alive, with two
recurrences, both in spine with CSF involvement, resulting in a disease free-survival and overall survival of 85.2%
and 90.2%, respectively.
Seven patients (17%) experienced POG Grade 3 or 4 toxicity. Cisplatin dose was a significant factor for hearing loss
in univariate analysis (p < 0.03). In multivariate analysis, median dose to inner ear was significantly associated with
hearing loss (p < 0.01). POG grade 3 and 4 toxicity were uncommon with median doses to the inner ear bellow
42 Gy (p < 0.05) and total cisplatin dose of less than 375 mg/m2 (p < 0.01).
Conclusions: IMRT leads to a low rate of severe ototoxicity. Median radiation dose to auditory apparatus should
be kept below 42 Gy. Cisplatin doses should not exceed 375 mg/m2.
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Introduction
Medulloblastoma is a common central nervous system
(CNS) tumor in pediatric patients, accounting for 15-20%
of all CNS tumors in this age group. Currently, the treat-
ment for medulloblastoma consists of maximal resection,
followed by postoperative radiotherapy (RT) of the intra-
cranial and spinal subarachnoid volume, plus a boost to
the posterior fossa (PF) or involved field (IF). Adjuvant
cisplatin-based chemotherapy is also used. This approach
results in a 5-year survival rate in up to 85% of standard
risk (SR) cases [1-3].
Neurosensorial hearing loss (NSHL) is a common com-
plication of treatment in children with medulloblastoma.
Hearing loss impairs the academic and social development
of these children [4]. Numerous studies have demon-
strated that the severity of NSHL increases with higher
RT doses to the inner ear [5,6]. Combined RT with
cisplatin-based chemotherapy can enhance ototoxicity in
children, mainly in high-frequency sounds. By minimizing
the radiation dose to the inner ear, the risk of hearing loss
can be reduced. Some studies have shown that the delivery
of IF boost only instead of the whole PF achieve similar
local control and survival rates compared to PF boost
[7,8]. With the development of intensity-modulated radi-
ation therapy (IMRT) it is now possible to further decrease
the dose to normal tissues, including the inner ear in pa-
tients with medulloblastoma, thus potentially reducing the
ototoxicity [9,10].
Hearing function is a complex human sense controlled
by delicate structures that can be affected by radiation,
whose impairment is attributed to changes in the cochlea
or vasculature. It is hypothesized that NSHL results from
cochlear damage [5-11]. The use of cisplatin in many pa-
tients also contributes to hearing loss, further complicat-
ing any attempt to determine a tolerance radiation dose.
Herein we performed a retrospective assessment of
hearing function in a cohort of medulloblastoma children
treated with IMRT. Our goal was to determine whether IF
boost with IMRT can achieve a lower rate of ototoxicity
and establish a threshold dose for the development of
hearing loss. We also analyzed if the total cisplatin dose
influenced the severity of NSHL.
Methods
Patients’ characteristics
This retrospective study was approved by the institu-
tional review board. Patients were included in the study
if they had: 1) normal hearing function at baseline; 2)
treatment with IMRT for the boost volume; 3) follow-
up ≥ one year; 4) age younger than 21. They were allocated
to either standard risk (SR) or high risk (HR) groups. From
February 2004 to August 2008, 41 patients with medullo-
blastoma were treated in the Department of Radiation
Oncology of Hospital Israelita Albert Einstein (HIAE)
and included in the study. These patients had maximal
resection that could be safely performed, followed by adju-
vant craniospinal irradiation (CSI) plus a boost to PF and/
or IF, and adjuvant chemotherapy. IMRT was used to
deliver the boost.
Treatment by group stratification
All patients in the study were submitted to CSI with
either conventional or conformal RT (3DRT) followed
by a PF and/or IF boost with IMRT.
SR patients received 23 to 24 Gy CSI, followed by either
a PF boost to 36 Gy and IF boost to 54 to 55.8 Gy (n = 10),
or IF boost only to 55.8 Gy (n = 5). Five SR patients re-
ceived 36 Gy CSI. HR patients were treated with 36 Gy
CSI followed by an IF boost to 54 to 55.8 Gy.
For staging, CSI and IMRT boost planning and treat-
ment, methods were similar as described by others [9,10],
except for the planning system (Eclipse™/Varian INC, Palo
Alto, CA).
For the study, dose-volume histograms were reviewed.
Minimum, maximum, mean and median doses to the
inner ear contoured in IMRT planning were obtained
and correlated with hearing function.
Chemotherapy protocols for SR patients consisted of
vincristine and etoposide during RT, followed by up to 8
cycles of cyclophosphamide, vincristine, and cisplatin six
weeks later. Patients stratified as HR received 3 cycles of
the same schema, before radiation followed by six months
of oral etoposide. Patients with leptomeningeal spread re-
ceived intravenous methotrexate. Twelve out of 20 SR
patients received at least 6 cycles of cisplatin. Three pa-
tients, due to toxicity, received 4 cycles and 6 patients
received carboplatin instead of cisplatin. In the HR group,
3 patients had carboplatin instead of cisplatin and only
one patient had the last cycle cancelled due to hemato-
logic complication. Mean cisplatin dose administrated on
patients was 286.2 mg/m2 (range 0 to 600 mg/m2). Each
patient’s record was analyzed individually to verify audi-
tory apparatus delineation whose pattern consisted of a
circular structure within the temporal bone including
cochlea and semicircular channels [12].
Hearing evaluation
All patients had normal hearing function at the begin-
ning of RT. Pure-tone audiograms were used to assess
hearing thresholds. The frequencies 250 Hz, 500 Hz,
1000 Hz, 2000 Hz, 3000 Hz, 4000 Hz, 6000 Hz and
8000 Hz were obtained and measured in decibel (dB)
hearing level. Hearing function was graded on scale 0 to
4 according to Pediatric Oncology group’s (POG) [9] tox-
icity criteria. Patients with POG grade 3 and 4 toxicity
were stratified as severe hearing loss group due to impair-
ment in hearing speech frequencies and learning abilities.
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Meanwhile, those with normal hearing and POG grade 1
and 2 toxicity were considered in the non-severe group.
The last audiogram performed from the beginning of
RT was considered for data analysis. Each ear was evalu-
ated individually, however as no difference between sides
was observed, a mean volume was calculated for data
analysis.
Outcomes
The primary outcome was to evaluate POG ototoxicity
grade in medulloblastoma patients treated with IF boost
using IMRT. Secondary outcomes were as follows: estab-
lish a relationship between the RT dose received by the
inner ear with POG ototoxicity and the cumulative cis-
platin dose with POG ototoxicity and analyze disease free
and overall survival.
Statistical analysis
POG’s ototoxicity grade was considered the final event for
audiometric follow-up whereas recurrence and survival
were considered end-points for disease free-survival and
overall survival respectively.
Correlation between ear’s right and left variables were
made by spearman correlation coefficient. A mean value
was obtained from both ears for final data analysis.
Univariate analysis for comparison between severe and
non-severe NSHL was performed with t-test for inde-
pendent variables. For the multivariate analysis, a logistic
regression model was used to study variables significance
over severe NSHL likelihood. After adjustment of all
variables, the least significant ones were excluded, result-
ing in reduced logistic regression model. ROC curves were
used to discriminate variables efficiency in severe POG
ototoxicity. Survival curves were estimated by Kaplan-
Meier method.
Results
Audiologic follow-up ranged from 12 to 71 months (mean
of 41 months). Mean doses for minimum, maximum,
mean and median in the inner ear were respectively:
37.85 Gy (range, 25.894 to 47.582 Gy), 48.325 Gy (range,
37.24 to 54.479 Gy), 43.665 (range, 28.085 to 50.973 Gy)
and 43.605 Gy (range, 28.78 to 50.311 Gy) (Table 1). POG
ototoxicity grade 0, 1, 2, 3 and 4 for the right and left ears
were 29.3%, 46.3%, 7.3%, 12.2%, 4.9% and 28.2%, 43.6%,
10.3%, 12.8%, 5.1%, respectively. Thirty-four (82.9%) pa-
tients had POG grades 0 to 2 whereas 7 patients (17.1%)
had severe ototoxicity (POG grade 3 or 4). Eleven (26.8%)
patients had normal hearing function at the last audio-
gram (POG grade 0) (Table 2).
Mean cisplatin dose administrated on patients was
286.22 mg/m2; the drug was not given to 9 (22%) patients
(Table 3).
Univariate analysis with t-test found no differences for
the variables between the two groups studied, except for
mean cumulative cisplatin dose (p < 0.01) (Table 4). Lo-
gistic regression model was performed in multivariate
analysis in order to study all variables impact on severe
ototoxicity (POG grade 3 and 4). Thereafter, the least
significant variables were excluded in the reduced logis-
tic regression model. Median RT dose to the auditory
apparatus was a statistically significant factor for POG
grade 3 and 4 (p = 0.012) whereas mean cumulative
cisplatin dose may play an important role (p = 0.075)
(Table 5).
Cut-off points to determine variables efficiency were
evaluated by ROC curves adjusted by reduced logistic
regression model (Table 6). According to this analysis,
cumulative cisplatin doses greater than 375 mg/m2 is an
important risk factor for severe ototoxicity (p < 0.01) and
Table 1 Variables description
Variable N Minimum Maximum Mean
Minimum dose (Gy) 41 25.894 47.582 37.85
Maximum dose (Gy) 41 37.24 54.479 48.325
Mean dose (Gy) 41 28.085 50.973 43.665
Median dose (Gy) 41 28.78 50.311 43.605
Audiologic follow-up (months) 41 12.83 71.00 41
Survival follow-up (months) 41 14 72 44
Age 41 2.9 19.8 10
Table 2 Categorized hearing loss according to POG grade
POG ototoxicity Frequence % % accumulated
0 - 2 34 82.9% 82.9%
3 - 4 7 17.1% 100%
Total 41 100%
Table 3 Mean cumulative cisplatin doses
Cisplatin dose (mg/m2) Frequence % % accumulated
0 9 22% 22%
270 6 14.6% 36.6%
300 3 7.3% 43.9%
315 1 2.4% 46.3%
360 3 7.3% 53.7%
390 1 2.4% 56.1%
420 1 2.4% 58.5%
425 1 2.4% 61.0%
450 11 26.8% 87.8%
495 1 2.4% 90.2%
540 1 2.4% 92.7%
600 3 7.3% 100%
Total 41 100%
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median dose to auditory apparatus greater than 42 Gy
increases patient’s chance to develop severe ototoxicity
(p < 0.05).
After a mean follow-up of 44 months (range, 14 to
72 months), 37 patients remained alive, with two recur-
rences, both in spine with CSF involvement, resulting in
a disease free-survival and overall survival of 85.2% and
90.2%, respectively.
Discussion
Our study shows that children with medulloblastoma can
enjoy a lengthy good hearing function after treatment with
postoperative chemoradiotherapy. The report of 17.1% of
severe ototoxicity among the 41 patients compares favor-
ably with the results of other studies [5-11,13] that have
reported the outcomes of minimizing dose to the cochlea
and hearing loss in medulloblastoma, besides being quite
lower than the rate seen when conventional RT was used.
In our study, both cisplatin and RT doses were import-
ant risk factors in developing severe ototoxicity. The radi-
ation limit dose for median auditory apparatus was 42 Gy
and the cumulative cisplatin dose was 375 mg/m2, both in
agreement with previous findings [9,10,13-15].
It is noteworthy that only 26.8% had no hearing deficit
at all and were stratified as POG grade 0, a concern also
noticed in other trials [5,6,8-11,13-15] that only few pa-
tients keep a normal hearing function in the long term,
supporting the use of IMRT to reduce the severity of
NSHL, allowing children to learn and develop normally.
In regard to survival rates, there was a concern among
radiation oncologists that IMRT could compromise local
control and survival because a greater conformality
obtained with IMRT could jeopardize isodoses curves
in the target. That was the reason why survival rates
were analyzed in the present study, although the median
follow-up was less than 60 months. Studies analyzing
boost with 3DRT and IMRT and reduced volume obtained
high survival and PF control rates [1,7,8,13], which is cor-
roborated by our findings, highlighting the fact that IMRT
is safe and doesn’t compromise local control and survival
due to any geographical miss of the target.
The t-test results used in the univariate analysis were
meant to be an introduction to a more sophisticated
statistical multivariate model of logistic regression. There
could be many reasons why the median dose to inner ear
was not significant on univariate analysis: the small sample
size of the group of patients who experienced the event
(n = 7), the underlying distribution of the median dose to
inner ear not being normal, among other reasons. The
statistically significant result for the median dose to inner
ear in the logistic regression analysis is stronger evidence
that there is an association between this factor and the
probability of a subject experiencing hearing loss than the
non-significant result of a t-test comparing the median
dose to inner ear of the two subgroups. Unfortunately, it
was not possible to establish the onset of ototoxicity since
not all patients did an audiogram on a regular schedule
due to travel issues, a weakness in this study.
Researches from Texas Children’s Hospital reported 13%
of ototoxicity in 15 medulloblastoma patients treated by
boost IMRT compared with 64% in 11 patients treated by
conventional RT [9]. This study had an update with a
longer median follow-up of 41months and 44 patients eval-
uated and showed many similarities between our study
[10]. POG grade 3 and 4 ototoxicity was seen in 25% of pa-
tients, whereas 25% of the patients had normal hearing
Table 4 Univariate analysis for ototoxicity
POG
ototoxicity
Frequence Mean Standard
error
p-value
Minimum dose 0-2 34 3725.5 940.7 0.612
3-4 7 3923.5 887.7
Maximum dose 0-2 34 4819.9 400.2 0.851
3-4 7 4849.8 246.0
Mean dose 0-2 34 4315.3 480.1 0.296
3-4 7 4513.8 241.6
Median dose 0-2 34 4313.1 443.2 0.280
3-4 7 4503.2 241.6
Mean cisplatin
dose (mg/m2)
0-2 34 288.68 196.759 0.003
3-4 7 445.71 88.620
Table 5 Reduced logistic regression model for POG
ototoxicity grade 3 e 4
Variable Coefficient Standard error p-value
Median dose (Gy) −0.001 0.000 0.012
Cisplatin dose (mg/m2) 0.006 0.003 0.075
Table 6 Reduced logistic regression model for cut-off
points
Variable Coefficient Standard
error
p-value Odds
ratio
Median < 42.04 Gy −2.191 1.180 0.043 0.112
Cisplatin dose < 375 mg/m2 −2.825 1.035 0.006 0.059
Figure 1 POG ototoxicity in patients who received carboplatin.
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function in both ears. All patients received cisplatin-based
chemotherapy. Median onset for the development of POG
grade 3 or 4 ototoxicity was 8.5 months after radiation,
which is quite lower than what is expected when RT is the
only treatment, that is, 2 to 4 years. There was a signifi-
cant correlation in mean cochlear doses with severity of
NSHL, aside from that; cochlear dose didn’t exceed 43 Gy
in all ears with normal hearing function.
The biggest difference between both studies was that
total cisplatin dose was not found in Paulino’s study to
correlate with the degree of ototoxicity due to the fact
that cisplatin dose was lowered when Grade 3 ototoxicity
was encountered. Hence, patients who had less than
Grade 3 ototoxicity had full doses of cisplatin and higher
cumulative doses.
Nevertheless, cisplatin is the drug with the greatest
ototoxicity potential known. Children are more prone
to such hearing damage which depends on the dose,
schedule and speed of infusion. On average, 50% of
patients show some deficit in higher frequencies (6 and
8 Hz) with cumulative doses greater than 450 mg/m2. In
children treated in combination with RT, this threshold
dose is reduced substantially, with doses as low as
270 mg/m2 being associated with a high probability of
NSHL. It has been observed that hearing acuity is either
not affected or only minimally decreased in children
treated only by RT [14,15]. As a matter of fact, doses to
the inner ear less than 40 Gy hardly ever causes ototox-
icity [11,14-16], however the threshold dose for NSHL
with cisplatin-based chemotherapy and RT can be as low
as 10 Gy [16-18]. Likewise, children with CNS shunting
have increased risk to develop NSHL and the mean RT
dose to the ear should to be limited in 45 Gy or even
conservatively below 36 Gy, mainly when combined to
cisplatin chemotherapy [11].
On the other hand, dose constraint below 35 Gy in the
inner ear is only feasible in medulloblastoma patients
with SR disease submitted to IF boost straight after 24
Gy CSI. Patients with HR disease, who need to be
treated with 36 Gy CSI and those with SR disease whose
boost is performed after a 36 Gy PF boost, usually re-
ceive doses above 40 Gy in the inner ear structures.
Our study was able to demonstrate that cisplatin plays
a major role in the development of NSHL and is aggra-
vated with increasing radiation dose to the cochlea. In
the group of 7 patients with severe ototoxicity, mean cu-
mulative dose was greater than in those whose hearing
level was POG grade 0 to 2 (445.71 × 288.68 mg/m2).
Moreover, none of the 9 patients who received carbopla-
tin had severe hearing loss (Figure 1).
Therefore, we can infer from our findings and Paulino’s
study that the benefit of dose reduction provided by IMRT
is quite dependable on cisplatin cumulative dose. Consid-
ering the impact of cisplatin on survival, it is sine qua non
to develop new strategies to decrease the side effects of
chemoradiation in children. Hyperbaric oxygen treatment
[19] and amifostin [20] has shown promising results in
reducing the risk of post-treatment sequelae and will be
our target for future trials.
Conclusion
IMRT is a safe and valuable tool to reduce severe ototox-
icity in medulloblastoma patients while achieving local
control and survival rates comparable to conventional RT.
RT and cisplatin doses should not exceed 42 Gy and
375 mg/m2, respectively.
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